High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P<0.001). The rates of partial response were similar (42 percent and 40 percent, respectively; P=0.72), and the rates of minimal response were lower in the intensive-therapy group than in the standard-therapy group (3 percent vs. 18 percent, P<0.001). Intention-to-treat analysis showed a higher rate of overall survival (P=0.04 by the log-rank test) and progression-free survival (P<0.001) in the intensive-therapy group than in the standard-therapy group. As compared with standard therapy, intensive treatment increased median survival by almost 1 year (54.1 months [95 percent confidence interval, 44.9 to 65.2] vs. 42.3 months [95 percent confidence interval, 33.1 to 51.6]). There was a trend toward a greater survival benefit in the group of patients with a poor prognosis, as defined by a high beta2-microglobulin level (more than 8 mg per liter). CONCLUSIONS: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASCT improves median OS in multiple myeloma by approximately 12 months.125–128”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [126]
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310
Research works printed but not linked: 7
- Morgan G, Selby P. Myeloma. In: Souhami R, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology. 2nd ed. Vol. 2. Oxford, England: Oxford University Press, 2001:2419-55.
- Lenhoff S, 2000, Blood, 95, 7
- Fermand J-P, 1999, Blood, 94, 396a
- Review manager (RevMan), version 4.1. Oxford, England: Cochrane Collaboration, 2000.
- Blade J, 2001, Blood, 98, 815a
- Segeren CM, 2001, Blood, 98, 815a
- Fermand J-P, 2001, Blood, 98, 815a
Cited by
Items 901–1,000 of 1,000
Preparation and biological evaluation of 166Ho-BPAMD as a potential therapeutic bone-seeking agent
Yousefnia, H., Amraei, N., Hosntalab, M., Zolghadri, S., & Bahrami‐Samani, A. (2015) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-014-3924-1 · Cited by 14
“arising from plasma cells in the bone marrow with fatal consequence [1].”
BackgroundPegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours
Willis, F., Woll, P. J., Theti, D. S., Jamali, H., Bacon, P., Baker, N. F., & Pettengell, R. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.411 · Cited by 14
The role of tandem stem cell transplantation for multiple myeloma patients
Martino, M. V., Recchia, A. G., Fedele, R., Neri, S., Vincelli, I. D., Moscato, T., Gentile, M., & Morabito, F. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1136285 · Cited by 16
Hari, P., Reece, D. E., Randhawa, J. K., Flomenberg, N., Howard, D. S., Badros, A. Z., Rapoport, A. P., Meisenberg, B. R., Filicko-O'Hara, J. E., Phillips, G. L., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0261-y · Cited by 14
Rifkin, R. M., Jagannath, S., Durie, B. G. M., Narang, M., Terebelo, H. R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Wagner, L. I., Parikh, K., et al. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.05.017 · Cited by 14
Hose, D., Beck, S., Salwender, H. J., Emde, M., Bertsch, U., Kunz, C., Scheid, C., Hänel, M., Weisel, K. C., Hielscher, T., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0750-5 · Cited by 15
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
Larsen, J. T., & Kumar, S. K. (2015) · Rare Cancers and Therapy · doi:10.1007/s40487-015-0009-4 · Cited by 14
“nonintensive therapy [25, 26].”
Fleming, S. A., Harrison, S. J., Blombery, P. A., Joyce, T., Stokes, K. H., Seymour, J. F., Prince, H. M., & Ritchie, D. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.02.001 · Cited by 14
Ghiaur, G., Gerber, J. M., Matsui, W. H., & Jones, R. J. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834ec015 · Cited by 14
“Even the most intensive therapy for myeloma, blood or marrow transplantation (BMT) [21,22], provided no overall survival advantage in the national intergroup trial [23] or in two recent meta-analyses [24,25].”
Talamo, G., Rakszawski, K. L., Rybka, W. B., Dolloff, N. G., Malysz, J., Berno, T., & Zangari, M. (2012) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2012.01795.x · Cited by 14
Treatment of relapsed and refractory myeloma
Reece, D. E., Leitch, H. A., Atkins, H. L., Voralia, M., Canning, L. A., LeBlanc, R., Belch, A. R., White, D. J., & Kovacs, M. J. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802064941 · Cited by 14
“Significant benefit in response and survival has been demonstrated for HDT-ASCT [2,3].”
BackgroundInfluentialPuig, N., Sarasquete, M. E., Alcoceba, M., Balanzategui, A., Chillón, C., Sebastián, E., Díaz, M. G., Miguel, J. F. S., & García‐Sánz, R. (2012) · European Journal Of Haematology · doi:10.1111/ejh.12000 · Cited by 14
Yang, H. Y., Robinson, S. N., Nieto, Y. L., Jones, R. J., Gocke, C. D., Lu, J., Giralt, S., Jones, R. B., Decker, W. K., Xing, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0842 · Cited by 14
Moreau, P., & Rajkumar, S. V. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.02.023 · Cited by 16
“Although not curative, ASCT has become the mainstay of reatment for patients less than 65 based on improved median verall survival of approximately 12–18 months compared with hemotherapy alone in 2 randomized trials [2,3].”
BackgroundMethodInfluentialShimazaki, C., Fujii, H., Yoshida, T., Chou, T., Nishimura, M., Asaoku, H., Miyawaki, S., Ishii, A., Ishida, T., Taniwaki, M., et al. (2005) · International Journal of Hematology · doi:10.1532/ijh97.04174 · Cited by 14
“Recently, highdose chemotherapy followed by autologous stem cell transplantation (SCT) has been demonstrated to be superior to conventional chemotherapy in terms of the complete response (CR) rate, event-free survival, and overall survival (OS) [1, 2 ].”
BackgroundChen, R., Tu, Y., Cao, Y., Liu, L., & Liang, Y. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900544 · Cited by 15
Benson, D. M., Panzner, K., Hamadani, M., Hofmeister, C. C., Bakan, C. E., Smith, M., Elder, P., Krugh, D., O’Donnell, L. C., & Devine, S. M. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903480728 · Cited by 14
Autologous transplantation for multiple myeloma
Harousseau, J. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn449 · Cited by 15
“Similar results were published 7 years later by the British Medical Research Council [2].”
Patel, D. A., Gopalakrishnan, R., Engelhardt, B. G., McArthur, E., Sengsayadeth, S. M., Culos, K., Byrne, M. T., Goodman, S. A., Savani, B. N., Chinratanalab, W., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0791-y · Cited by 14
Vaxman, I., Muchtar, E., Jacob, E., Kapoor, P., Kumar, S. K., Dispenzieri, A. A., Buadi, F. K., Dingli, D., Gonsalves, W. I., Kourelis, T., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.06.016 · Cited by 14
Immunomodulatory Analogues of Thalidomide in the Treatment of Multiple Myeloma
Suppiah, R., Srkalovic, J. G., & Hussein, M. A. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.004 · Cited by 15
Stem Cell Transplantation in Multiple Myeloma
Attal, M., Moreau, P., Avet‐Loiseau, H., & Harousseau, J. (2007) · Hematology · doi:10.1182/asheducation-2007.1.311 · Cited by 17
“How to improve the outcome of ASCT: the impact of new drugs The introduction of novel agents such as thalidomide (THAL), bortezomib or lenalidomide in the HDT is logical and has been actively investigated to try to improve the quality of response: (1) the induction therapy, (2) HDT, and (3) maintenance therapy after A…”
BackgroundMel, S. D., Chen, Y., Gopalakrishnan, S., Ooi, M. G. M., Teo, C., Tan, D., Teo, M., Tso, A. C. Y., Lee, L. Y. K., Nagarajan, C., et al. (2017) · Singapore Medical Journal · doi:10.11622/smedj.2016150 · Cited by 14
Ogunniyi, A., Rodríguez, M., Devlin, S. M., Adel, N. G., Landau, H. J., Chung, D. J., Lendvai, N. K., Lesokhin, A. M., Koehne, G., Mailankody, S., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1239261 · Cited by 15
Mina, R., Petrucci, M. T., Corradini, P., Spada, S., Patriarca, F. F., Cerrato, C., Paoli, L. D., Pescosta, N., Ria, R., Malfitano, A., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.05.019 · Cited by 15
Rossi, G., Falcone, A. P., Minervini, M. M., Cillis, G. P. D., de Waure, C., Sisti, L. G., Giambra, V., Valente, D., Chiello, V., Scalzulli, P. R., et al. (2018) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21755 · Cited by 15
“Based on reported data, consolidation with highdose alkylating agents and autologous stem cell transplantation (ASCT) represent the conventional treatment for transplant-eligible patients with multiple myeloma (MM) (1,2).”
BackgroundGonzalez‐McQuire, S., Dimopoulos, M. A., Weisel, K. C., Bouwmeester, W., Hájek, R., Campioni, M., Bennison, C., Xu, W., Pantiri, K., Hensen, M., et al. (2019) · MDM Policy & Practice · doi:10.1177/2381468318814253 · Cited by 14
“Two randomized clinical trials have shown that high-dose chemotherapy followed by autologous SCT is associated with an improved response rate, event-free survival, and OS compared with conventional chemotherapy.(36,37) In addition, the shorter OS in older patients may be due to discontinuation of treatment.”
BackgroundClinical treatment of newly diagnosed multiple myeloma
Cejalvo, M. J., & de la Rubia, J. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1078236 · Cited by 15
“Consequently, frontline induction followed by intensive therapy with ASCT resulted in the standard of care in this subgroup of patients [8,9].”
MethodComenzo, R. L., Hassoun, H., Kewalramani, T., Klimek, V. M., Dhodapkar, M. V., REICH, L. M., Teruya‐Feldstein, J., Fleisher, M., Filippa, D., & Nimer, S. D. (2005) · Leukemia · doi:10.1038/sj.leu.2404003 · Cited by 14
Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma
Arora, M., McGlave, P. B., Burns, L. J., Miller, J. S., Barke, J. N., DeFor, T. E., & Weisdorf, D. J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704968 · Cited by 14
Pineda‐Roman, M., Barlogie, B., Anaissie, E. J., Zangari, M., Bolejack, V., van Rhee, F., Tricot, G. J. K., & Crowley, J. J. (2008) · Cancer · doi:10.1002/cncr.23327 · Cited by 15
“MEL 200 (69) MEL 200 3 2 (63) MEL 200 3 2, BEAM (21) MEL 200 3 2, other regimens (100) MEL 140 TBI (21) MEL 200, MEL 140 1 TBI (10) MEL 200 3 3 (18) Other MEL regimens (10) MEL 200, BEAM (10) MEL 200 3 2, Allo (17) MEL 200, Allo (5) MEL 200 3 2, MEL 140 (12) MEL140 3 2 TBI (4) MEL 200 or MEL 140 3 2, other regimens (3…”
Multiple myeloma: The role of transplant and novel treatment strategies
Kaufman, J. L., & Lonial, S. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.02.015 · Cited by 15
Singhal, S. (2003) · BMJ · doi:10.1136/bmj.327.7415.575 · Cited by 14
“The superiority of consolidation with haematopoietic stem cell transplantation over continued conventional treatment has been confirmed in two randomised studies with a 12 month increase in median overall survival.”
BackgroundBelizaire, R., Sykes, D. B., Chen, Y.-B. A., Spitzer, T. R., & Makar, R. S. J. (2015) · Transfusion · doi:10.1111/trf.13125 · Cited by 13
Harrison, S. J., FRANKLIN, I. M., & Campbell, J. D. M. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802464729 · Cited by 13
Sahebi, F., Shen, Y., Thomas, S. H., Rincon, A., Murata‐Collins, J. L., Palmer, J. M., Krishnan, A. Y., Karanes, C., Htut, M., Somlo, G., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12123 · Cited by 14
“…and allogeneic transplantation have been shown to improve long-term 202 ª 2012 Blackwell Publishing Ltd British Journal of Haematology, 2013, 160, 199–206 survival (Attal et al, 1996; Child et al, 2003), with lower relapse rates for allo-HCT compared to auto-HCT (Bjorkstrand et al, 1996, 2009).”
BackgroundGao, S., Li, Q., Dong, F., Yang, P., Chen, Y., Wang, J., Wang, Y., & Jing, H. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106793 · Cited by 13
Kauer, J., Freundt, E. P., Schmitt, A., Weinhold, N., Mai, E. K., Müller‐Tidow, C., Goldschmidt, H., Raab, M. S., Kriegsmann, K., & Sauer, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11507-9 · Cited by 14
“While a single treatment with HDCT/ABSCT prolongs overall survival (OS) [4, 5], tandem treatment might improve outcomes even further and is used in some countries (i.e., Germany) [6, 7].”
BackgroundIs There a Role for Autotransplants in AML in First Remission?
Seshadri, T., & Keating, A. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.11.016 · Cited by 13
Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
Al‐Mansour, Z., & Ramanathan, M. (2014) · Advances in Hematology · doi:10.1155/2014/652395 · Cited by 14
“…stem cell transplant (ASCT) is the standard of care in transplant-eligible patients, based on several phase III trials and meta-analyses in the mid-1990s showing significant improvement in progression-free survival (PFS) and complete remission rates (CR) as well as overall survival (OS) [1–3].”
BackgroundInitial treatment of transplant-eligible patients in multiple myeloma
Rosiñol, L., Kumar, S. K., Moreau, P., & Cavo, M. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.871200 · Cited by 14
“Upfront versus delayed ASCT Before the introduction of new drugs, the standard approach for young patients with de novo MM was an induction based on dexamethasone or conventional chemotherapy followed by HDM and stem cell transplantation (SCT), although only two [50,51] of five randomized clinical trials [50–54] compa…”
BackgroundBleeker, J. S., Gertz, M. A., Pellikka, P. A., Larson, D. R., Buadi, F. K., Dingli, D., Dispenzieri, A. A., Hayman, S. R., Hogan, W. J., Kumar, S. K., et al. (2012) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2012.01815.x · Cited by 13
Lee, S. R., Kim, S. J., Park, Y., Sung, H. J., Choi, C. W., & Kim, B. S. (2010) · The Korean Journal of Hematology · doi:10.5045/kjh.2010.45.3.183 · Cited by 13
“Intravenous administration of high-dose of melphalan followed by autologous stem cell transplantation (ASCT) induces higher response rates and improved treatment outcomes compared to that with standard dose melphalan, as reported in previous randomized trials [1, 2].”
ResultRaab, M., Cremer, F. W., Breitkreutz, I., Gerull, S., Luft, T., Benner, A., Göerner, M., Ho, A. D., Goldschmidt, H., & Moos, M. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi123 · Cited by 13
Partanen, A., Valtola, J., Silvennoinen, R. H., Ropponen, A., Siitonen, T., Putkonen, M., Sankelo, M., Pelkonen, J., Mäntymaa, P., Varmavuo, V., et al. (2017) · Transfusion · doi:10.1111/trf.14220 · Cited by 16
“0-54 days in the LEN[2] group) to achieve a platelet count greater than 20 310(9)/L in both groups (p 5 0.”
BackgroundCheung, C. H. Y., Cheng, C. K., Lau, K., Ip, R. K. L., Chan, N. C. N., Tam, T. H. C., Wong, R. S. M., Raghupathy, R., Chan, N. P. H., & Ng, M. H. L. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.05.008 · Cited by 13
High-Dose Therapy in Patients with Plasma Cell Dyscrasias and Renal Dysfunction
Pineda‐Roman, M., & Tricot, G. J. K. (2006) · KARGER eBooks · doi:10.1159/000096767 · Cited by 13
Zamagni, E., Petrucci, A., Tosi, P., Tacchetti, P., Perrone, G., Brioli, A., Pantani, L., Zannetti, B. A., Terragna, C., Baccarani, M., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1320-2 · Cited by 13
Huang, H., Wu, D., Fu, J., Chen, G., Chang, W., Chow, H. C. H., Leung, A. Y. H., & Liang, R. H. S. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01277.x · Cited by 13
“Although many approaches have improved treatment outcome, most patients are incurable with the current treatment modalities and the median survival is about 42 months (2).”
Hematological malignancies: myeloma
Dimopoulos, M. A., Kastritis, E., & Anagnostopoulos, Α. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl251 · Cited by 16
Phipps, C., Linenberger, M. L., Holmberg, L., Green, D., Becker, P. S., Connelly‐Smith, L. S., Klippel, Z. K., Burwick, N. R., Gopal, A. K., Bensinger, W., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.13 · Cited by 13
Raje, N. S., Faiman, B. M., Harvey, R. D., Kurtin, S. E., Lonial, S., Kumar, S. K., Cohen, A. D., Conde, M. Á., Giralt, S., Recine, M. S., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.04.011 · Cited by 13
Warner, J. L., Alterovitz, G., Bodio, K., & Joyce, R. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-001355 · Cited by 13
Saleh, A. S. A., Sidiqi, M. H., Lee, J., Dispenzieri, A. A., Muchtar, E., Buadi, F. K., Warsame, R. M., Lacy, M. Q., Dingli, D., Leung, N., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0916-3 · Cited by 13
Stem Cell Transplantation for Multiple Myeloma
Gasparetto, C. (2004) · Cancer Control · doi:10.1177/107327480401100218 · Cited by 14
Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Kumar, S. K. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0083-0 · Cited by 15
“A series of large phase 3 trials confirmed a survival advantage for SCT over conventional therapy [15, 16 ], but it was clear that not all patients derived a survival benefit, as the OS advantage was not observed uniformly in the different trials [17].”
BackgroundWåhlin, A., Eriksson, M., & Hultdin, M. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00297.x · Cited by 13
“Improved response rates and significantly improved survival times have been reported for patients with multiple myeloma included in high-dose chemotherapy protocols compared with conventionally treated historic controls (1, 2) or patients randomised to standard treatment (3, 4).”
BackgroundMethodResultOchiai, N., Yamada, N., Uchida, R., Fuchida, S., Okano, A., Hatsuse, M., Okamoto, M., Ashihara, E., & Shimazaki, C. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05049 · Cited by 13
“Several chemotherapeutic regimens for MM have been developed, and only high-dose melphalan supported by autologous stem cell transplantation (auto-SCT) has improved the survival prospects of patients with MM [1-3].”
BackgroundHigh-dose therapy in multiple myeloma
Harousseau, J. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf638 · Cited by 13
Jantunen, E., Partanen, A., Turunen, A., Varmavuo, V., & Silvennoinen, R. H. (2023) · Transfusion Medicine and Hemotherapy · doi:10.1159/000531940 · Cited by 12
“Earlyrandomized transplantation studies in MM patients were performed in patients younger than 65 years of age [4, 5].”
Treatment of newly diagnosed multiple myeloma: advances in current therapy
Kumar, S. K. (2009) · Medical Oncology · doi:10.1007/s12032-009-9370-1 · Cited by 13
“(MRC VII) [19] ASCT 200 86 44 31.”
ResultInfluentialCurrent Approaches to the Initial Treatment of Symptomatic Multiple Myeloma
Jasielec, J. K., & Jakubowiak, A. J. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.3 · Cited by 13
Sinha, S., Rajkumar, S. V., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Dispenzieri, A. A., Dingli, D., Kyle, R. A., Gertz, M. A., & Kumar, S. K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08023.x · Cited by 12
Kazandjian, D. G., & Landgren, O. (2019) · PubMed · Cited by 15
Bal, S., Dhakal, B., Silbermann, R. W., Schmidt, T. M., Dholaria, B., Giri, S., Chhabra, S., Medvedova, E., Godby, K. N., D’Souza, A., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26640 · Cited by 13
Histone deacetylase inhibitors in multiple myeloma
Deleu, S., Menu, E., Valckenborgh, E. V., Camp, B. V., Fraczek, J., Broek, I. V., Rogiers, V., & Vanderkerken, K. (2009) · Hematology Reports · doi:10.4081/hr.2009.e9 · Cited by 12
“High-dose therapy plus autologous stem cell transplantation is considered the standard therapy for front-line treatment of MM patients aged <65 years.(12,13) The most common pre-transplantation induction therapies used today are thalidomide-dexamethasone, bortezomib-based regimes, and lenalidomide-dexamethasone.”
BackgroundCorso, A., Zappasodi, P., Barbarano, L., Petrucci, M. T., Palumbo, A., Caravita, T., Mangiacavalli, S., Cafro, A. M., Varettoni, M., Gay, F., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.03.015 · Cited by 12
Driscoll, J. J., Burris, J. K., & Annunziata, C. M. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181ff7a9e · Cited by 13
“As initial therapy in newly diagnosed or relapsed patients, SCT is generally not curative but has been shown to prolong survival.(7,8) Additionally, in selected patients, multiple SCTs may be employed.”
BackgroundMyeloma Kidney: Improving Clinical Outcomes?
Haynes, R., Leung, N., Kyle, R. A., & Winearls, C. G. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.03.001 · Cited by 12
Oncology: Treatment of Multiple Myeloma in the Targeted Therapy Era
Saad, A. A., Sharma, M. R., & Higa, G. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l428 · Cited by 13
Standardisation of minimal residual disease in multiple myeloma
Innao, V., Allegra, A., Russo, S., Gerace, D. G., Vaddinelli, D., Alonci, A., Allegra, A. G., & Musolino, C. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12732 · Cited by 15
“In the past era, with older anti- myeloma drugs, i.e. high- dose melphalan (HDM) followed by autologous stem cell transplantation (ASCT), the CR rate in newly diagnosed multiple myeloma (NDMM) was <50%, and still less sCR rate (Attal et al., 1996; Child et al., 2003).”
BackgroundUematsu, A., Kido, K., Manabe, E., Takeda, H., Takahashi, H., Hayashi, M., Imai, Y., & Sawasaki, T. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.142 · Cited by 12
Jung, S., Lee, J., Kim, J. S., Min, C., Kım, K., Choi, Y., Eom, H., Joo, Y. D., Kim, S., Kwak, J., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.004 · Cited by 12
Kollu, V. S., Magalhaes-Silverman, M. D., Tricot, G. J. K., & İnce, D. (2018) · Case Reports in Infectious Diseases · doi:10.1155/2018/9409121 · Cited by 12
“Despite the many advances in supportive care, infections continue to complicate the posttransplant course in many patients [4].”
BackgroundDimopoulos, M. A., & Kyle, R. A. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-817-5_8 · Cited by 12
Stefanou, D. T., Episkopou, H. G., Kyrtopoulos, S. Α., Bamias, A., Gkotzamanidou, M. A., Bamia, C., Liakou, C. A., Bekyrou, M., Sfikakis, P. P., Dimopoulos, M. A., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04274.x · Cited by 14
Thalidomide-induced acute cholestatic hepatitis: Case report and review of the literature
Boas, F. V., Gonçalves, R., Sobrinho-Simões, M. A., Lopes, J., & Macedo, G. (2012) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2012.05.007 · Cited by 12
Isshiki, I., Okamoto, S., Kakimoto, T., Chen, C. K., Mori, T., Yokoyama, K., Hattori, Y., & Ikeda, Y. (2006) · International Journal of Hematology · doi:10.1532/ijh97.06029 · Cited by 12
Eom, H., Kim, Y., Chung, J.-S., Kım, K., Kim, H. J., Kim, H. Y., Jin, J., Do, Y.-R., Oh, S., Suh, C., et al. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0871-y · Cited by 12
“The introduction of high-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (AHSCT) has improved the survival of patients with multiple myeloma (MM) [1, 2].”
BackgroundU nited K ingdom M yeloma F orum ( UKMF ) position statement on the use of bendamustine in myeloma
Pratt, G., Bowcock, S. J., Lai, M., Bell, S., Bird, J. M., D’Sa, S., Cavenagh, J. D., Cook, G., Morgan, G. J., Owen, R. G., et al. (2013) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12097 · Cited by 12
Self-citationMultiple myeloma: a ten year study of survival and therapy in a developing nation.
Omoti, C. E., & Omuemu, C. E. (2007) · PubMed · Cited by 13
Miller, K. C., Gertz, M. A., Buadi, F. K., Hayman, S. R., Wolf, R. C., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Kapoor, P., Gonsalves, W. I., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0302-6 · Cited by 13
The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma
Miller, K. C., Gertz, M. A., Buadi, F. K., Hayman, S. R., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Kapoor, P., Gonsalves, W. I., Kourelis, T., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0590-5 · Cited by 12
Muñoz, A., Riber, C., Satué, K., Trigo, P., Gómez-Díez, M., & Castejo, F. M. (2013) · InTech eBooks · doi:10.5772/54311 · Cited by 12
“Contamination of most bone marrow and blood stem cell samples with neoplastic cells within the auto‐ graph resulted in recurrence of disease, emphasizing the need of optimize purging techni‐ ques [246-250].”
BackgroundGertz, M. A., Leung, N., Lacy, M. Q., & Dispenzieri, A. A. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00559.x · Cited by 12
Current treatment options for myeloma
Terpos, E., Rahemtulla, A., & Dimopoulos, M. A. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.7.1127 · Cited by 14
“The CR rate was higher in the transplant group (44 versus 8%), as was the median OS (54 versus 42 months) and PFS (32 versus 20 months) [23].”
BackgroundGojo, I., Meisenberg, B. R., Guo, C., Fassas, A., Murthy, A., Fenton, R., Takebe, N., Heyman, M., Philips, G., Cottler‐Fox, M., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705192 · Cited by 12
Current status of new drugs for the treatment of patients with multiple myeloma
Kenealy, M. K., & Prince, H. M. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01218.x · Cited by 14
Dendritic Cells in Clinical Trials for Multiple Myeloma
Reichardt, V. L., & Brossart, P. (2004) · Humana Press eBooks · doi:10.1385/1-59259-862-5:127 · Cited by 12
Liu, S., & Hite, D. (2013) · RePEc: Research Papers in Economics · doi:10.22004/ag.econ.143045 · Cited by 21
Dimopoulos, M. A., Ntanasis‐Stathopoulos, I., Fotiou, D., Theodorakakou, F., Solia, E., Spiliopoulou, V., Malandrakis, P., Psimenou, E., Giannouli, S., Kanellias, N., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70012 · Cited by 12
Joks, M., Jurczyszyn, A. J., Machaczka, M., Skotnicki, A. B., & Komarnicki, M. A. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12412 · Cited by 12
Zhang, X., Zhang, C., Yang, X., Hou, X., Zhao, W., Benson, D., Yu, J., & Dong, Y. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.12.024 · Cited by 11
The impact of pulmonary function in patients undergoing autologous stem cell transplantation
Duque‐Afonso, J., Ewald, S., Ihorst, G., Waterhouse, M., Strüßmann, T., Zeiser, R., Wäsch, R., Bertz, H., Müller–Quernheim, J., Duyster, J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004863 · Cited by 11
Narsipur, N., Bulla, S., Yoo, C., Do, B., Tran, K., Gu, D., Zhong, L., & Wilson, L. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.12.1691 · Cited by 13
Newly diagnosed multiple myeloma: making sense of the menu
Costello, C. L. (2022) · Hematology · doi:10.1182/hematology.2022000404 · Cited by 12
Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
Gillich, C., Akhoundova, D., Hayoz, M., Aebi, Y., Largiadèr, C. R., Seipel, K., Daskalakis, M., Bacher, U., & Pabst, T. (2023) · Cancers · doi:10.3390/cancers15102699 · Cited by 11
High‐dose Preparatory Regimens
Bensinger, W. (2009) · Wiley eBooks · doi:10.1002/9781444303537.ch22 · Cited by 11
Annunziata, M., Celentano, M., Pocali, B., D’Amico, M. R., Palmieri, S., Viola, A., Copia, C., Falco, C., Vecchio, L. D., & Ferrara, F. (2006) · Annals of Hematology · doi:10.1007/s00277-005-0058-0 · Cited by 11
Who should be really considered as a poor mobilizer in the plerixafor era?
Andreola, G., Vanazzi, A., Radice, D., Babić, A., Rabascio, C., Negri, M., Martinelli, G., & Laszlò, D. (2012) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2012.03.004 · Cited by 11
Metadata
- Authors
- Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J.
- Affiliations
- University of Leeds (GB)
- University of Birmingham (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-05-08
- Volume
- 348
- Issue
- 19
- Pages
- 1875-1883
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102591890
- Semantic Scholar
- 5d90e1ff237e9db8f41e6e1e264450eed3f77e40
- Cited by
- 1,768
- References
- 23
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 41 · 2021: 57 · 2020: 83 · 2019: 46 · 2018: 71 · 2017: 76 · 2016: 73 · 2015: 71 · 2014: 81 · 2013: 103 · 2012: 94
- FWCI
- 53.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, high-dose chemotherapy, autologous stem cell transplantation, first-line therapy, complete response, overall survival, progression-free survival, beta2-microglobulin, prognostic factors, previously untreated myeloma
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cause of Death, Combined Modality Therapy, Cyclophosphamide, Doxorubicin, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.